Welcome to our dedicated page for Z Squared news (Ticker: ZSQR), a resource for investors and traders seeking the latest updates and insights on Z Squared stock.
Z Squared Inc. (ZSQR) news centers on the company’s shift into computing infrastructure and planned AI colocation. The main news themes are energized site acquisitions, power availability, high-density electrical and cooling design, and the steps needed to turn powered campuses into customer-ready infrastructure.
Company announcements have highlighted the acquisition of Paradox Data, LLC and the Union County Campus in El Dorado, Arkansas. That campus is important to the Z Squared story because the company described it as its first owned, energized campus and a base for advancing its planned AI colocation business. News about utility arrangements, on-site generation planning, adjacent land rights, customer service requests, permitting, financing, and construction can affect how that strategy develops.
Z Squared also generates news tied to public-company structure. Relevant categories include material agreements, acquisition disclosures, capital-structure updates, governance matters, registration statements, and operating or financial results. The company has also disclosed the spin-out of substantially all legacy biopharmaceutical operations, while GEAR Therapeutics remained a subsidiary.
For readers following ZSQR stock, the most useful news is not limited to earnings headlines. Z Squared’s updates often connect corporate finance, power-led infrastructure development, and acquisition activity. Regular review of Z Squared news can provide context on how the company is building its AI infrastructure platform and how its disclosed agreements fit into that plan.
Z Squared (Nasdaq: ZSQR) announced completion of its business combination with Coeptis Therapeutics and a Nasdaq Global Market listing under ticker ZSQR, effective April 27, 2026 (CUSIP: 98878K108). The closing followed SEC effectiveness of the Form S-4 and Coeptis stockholder approval.
Following the transaction, the combined company has ~51.5 million shares outstanding; former Z Squared Opco stockholders own ~85% and existing public stockholders own ~15%. Coeptis effected a pro rata distribution of its pre-combination biopharmaceutical subsidiary ownership to its record-date stockholders.